BAY59-7939 (rivaroxaban)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BAY59-7939 (rivaroxaban), covering 2014-12-23 to 2014-12-23. Get the full timeline:
Most recent: Clinical Trial Update: An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study [Phase 2]